APGE — Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 196
• Website: https://www.apogeetherapeutics.com

Latest SEC filings for APGE

• 15-12G — 2026-09-14
• SCHEDULE 13D/A — 2026-09-08
• S-8 POS — 2026-09-03
• 25-NSE — 2026-09-03
• POSASR — 2026-09-03
• S-8 POS — 2026-09-03
• S-8 POS — 2026-09-03
• S-8 POS — 2026-09-03
• S-8 POS — 2026-09-03
• SCHEDULE 13D/A — 2026-09-03

Abrir análisis completo

Educational tool only — not investment advice.